IMM-BCP-01 in Mild to Moderate COVID-19

NCT05429021 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision to discontinue the study based on strategic prioritization.

Conditions

SARS-CoV2 Infection
COVID-19

Interventions

DRUG: IMM-BCP-01
DRUG: Placebo

Sponsor

Immunome, Inc.

Collaborators

[object Object]